US5466445A
(en)
*
|
1985-06-18 |
1995-11-14 |
Emory University |
Methods for reducing salmonella in chickens
|
US5494660A
(en)
*
|
1985-06-18 |
1996-02-27 |
Emory University |
Method for inhibiting microbial binding to surfaces
|
USRE35862E
(en)
*
|
1986-08-18 |
1998-07-28 |
Emisphere Technologies, Inc. |
Delivery systems for pharmacological agents encapsulated with proteinoids
|
US5451410A
(en)
*
|
1993-04-22 |
1995-09-19 |
Emisphere Technologies, Inc. |
Modified amino acids for encapsulating active agents
|
US5541155A
(en)
*
|
1994-04-22 |
1996-07-30 |
Emisphere Technologies, Inc. |
Acids and acid salts and their use in delivery systems
|
US5447728A
(en)
*
|
1992-06-15 |
1995-09-05 |
Emisphere Technologies, Inc. |
Desferrioxamine oral delivery system
|
AU775214B2
(en)
*
|
1994-05-24 |
2004-07-22 |
Yeda Research And Development Co. Ltd. |
Copolymer-1 improvements in compositions of copolymers
|
AU741590B2
(en)
*
|
1994-05-24 |
2001-12-06 |
Yeda Research And Development Co. Ltd. |
Copolymer-1 improvements in compositions of copolymers
|
US5800808A
(en)
*
|
1994-05-24 |
1998-09-01 |
Veda Research And Development Co., Ltd. |
Copolymer-1 improvements in compositions of copolymers
|
US6090958A
(en)
*
|
1995-03-31 |
2000-07-18 |
Emisphere Technologies, Inc. |
Compounds and compositions for delivering active agents
|
US5858964A
(en)
*
|
1995-04-14 |
1999-01-12 |
Yeda Research And Development Co. Ltd. |
Pharmaceutical compositions comprising synthetic peptide copolymer for prevention of GVHD
|
US5820881A
(en)
*
|
1995-04-28 |
1998-10-13 |
Emisphere Technologies, Inc. |
Microspheres of diamide-dicarboxylic acids
|
US5824345A
(en)
*
|
1995-06-07 |
1998-10-20 |
Emisphere Technologies, Inc. |
Fragrances and flavorants
|
IL116559A
(en)
|
1995-11-17 |
2005-11-20 |
Yissum Res Dev Co |
Chimeric protein consisting of a bacterial toxin and a myelin basic protein sequence
|
AU2595697A
(en)
|
1996-03-29 |
1997-10-22 |
Emisphere Technologies, Inc. |
Compounds and compositions for delivering active agents
|
US6214791B1
(en)
*
|
1997-01-10 |
2001-04-10 |
Yeda Research And Development Co. Ltd. |
Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1
|
US6313088B1
(en)
|
1997-02-07 |
2001-11-06 |
Emisphere Technologies, Inc. |
8-[(2-hydroxy-4-methoxy benzoyl) amino]-octanoic acid compositions for delivering active agents
|
US5804688A
(en)
*
|
1997-02-07 |
1998-09-08 |
Emisphere Technologies, Inc. |
Compounds and compositions for delivering active agents
|
US5863944A
(en)
*
|
1997-04-30 |
1999-01-26 |
Emisphere Technologies, Inc. |
Compounds and compositions for delivering active agents
|
US5962710A
(en)
*
|
1997-05-09 |
1999-10-05 |
Emisphere Technologies, Inc. |
Method of preparing salicyloylamino acids
|
EP1105414A2
(fr)
|
1998-07-23 |
2001-06-13 |
President And Fellows of Harvard College |
Peptides synthetiques et procedes d'utilisation de ceux-ci dans des therapies de maladies auto-immunes
|
ES2527760T3
(es)
*
|
1998-07-23 |
2015-01-29 |
Yeda Research And Development Co., Ltd. |
Tratamiento de enfermedad de Crohn con copolímero 1 y polipéptidos
|
WO2000005250A1
(fr)
|
1998-07-23 |
2000-02-03 |
Yeda Research And Development Co., Ltd |
Traitement de maladies auto-immunes a l'aide du copolymere 1 et des copolymeres et peptides apparentes
|
US6800287B2
(en)
|
1998-09-25 |
2004-10-05 |
Yeda Research And Development Co., Ltd. |
Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use
|
US7083777B1
(en)
|
1999-04-02 |
2006-08-01 |
The Brigham And Women's Hospital, Inc. |
Immunomodulating polymers
|
US6531130B1
(en)
*
|
1999-07-06 |
2003-03-11 |
The Board Of Trustees Of The Leland Stanford University |
Treatment of demyelinating autoimmune disease with ordered peptides
|
CN100360180C
(zh)
*
|
2000-01-20 |
2008-01-09 |
耶达研究及发展有限公司 |
共聚物1和相关肽和多肽及其处理过的t细胞在神经保护性治疗中的用途
|
ZA200206457B
(en)
*
|
2000-02-18 |
2003-08-13 |
Yeda Res & Dev |
Oral, nasal and pulmonary dosage formulations of copolymer 1.
|
US20020077278A1
(en)
*
|
2000-06-05 |
2002-06-20 |
Yong V. Wee |
Use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders
|
CA2398277C
(fr)
*
|
2000-06-07 |
2013-09-03 |
Yeda Research And Development Co. Ltd. |
Utilisation de copolymere 1 et de peptides et polypeptides connexes et cellules t traitees a l'aide de ces produits pour proteger des cellules du systeme nerveux central de la toxicite du glutamate
|
WO2001097785A2
(fr)
*
|
2000-06-20 |
2001-12-27 |
Caprion Pharmaceuticals Inc. |
Copolymeres et methodes de traitement des maladies a prions
|
WO2002076503A1
(fr)
|
2000-06-20 |
2002-10-03 |
Mayo Foundation For Medical Education And Research |
Traitement de maladies du systeme nerveux central au moyen d'anticorps diriges contre l'acetate de glatiramere
|
IL137460A0
(en)
*
|
2000-07-24 |
2001-07-24 |
Yeda Res & Dev |
Identifying antigen clusters for monitoring a global state of an immune system
|
US20040037828A1
(en)
|
2002-07-09 |
2004-02-26 |
Bar-Ilan University |
Methods and pharmaceutical compositions for healing wounds
|
SV2003000753A
(es)
|
2000-12-05 |
2003-06-16 |
Brigham & Womens Hospital |
Uso de polisacaridos zwitterionicos para la especifica modulacion del progreso inmunologico
|
US7429374B2
(en)
*
|
2001-12-04 |
2008-09-30 |
Teva Pharmaceutical Industries, Ltd. |
Process for the measurement of the potency of glatiramer acetate
|
US7351686B2
(en)
*
|
2001-12-06 |
2008-04-01 |
Yeda Research And Development Co. Ltd. |
Method for neuronal protection in amyotrophic lateral sclerosis by a vaccine comprising Copolymer-1 or Copolymer-1 related peptides
|
EP1565486A2
(fr)
*
|
2002-11-13 |
2005-08-24 |
Apotex Pharmachem Inc. |
Procede de preparation de l'acetate de glatiramer par le polymerisation d'un anhydride n-carboxy de la l-alanine, l-tyrosine, l-glutamate benzolique et l-lysine benzoloxycarbonyl
|
EP1603530A1
(fr)
*
|
2003-03-04 |
2005-12-14 |
Teva Pharmaceutical Industries Limited |
Traitement combine a base d'acetate de glatiramer et d'alphacalcidol, destine au traitement de la sclerose en plaques
|
EP1638581A2
(fr)
*
|
2003-03-31 |
2006-03-29 |
The Brigham And Women's Hospital, Inc. |
Immunomodulateurs zwitterioniques destines au traitement de l'asthme et des allergies
|
NZ546379A
(en)
*
|
2003-10-31 |
2010-04-30 |
Teva Pharma |
Nanoparticles for drug delivery
|
AU2004288654B2
(en)
|
2003-11-12 |
2009-12-03 |
Yeda Research And Development Co. Ltd. |
Vaccine and method for treatment of neurodegenerative diseases
|
MXPA06010043A
(es)
*
|
2004-03-01 |
2007-03-07 |
Peptimmune Inc |
Metodos y composiciones para el tratamiento de enfermedades autoinmunologicas.
|
US20050260770A1
(en)
*
|
2004-04-01 |
2005-11-24 |
Cohen Irun R |
Antigen array and diagnostic uses thereof
|
US20060194725A1
(en)
*
|
2004-05-07 |
2006-08-31 |
James Rasmussen |
Methods of treating disease with random copolymers
|
BRPI0510738A
(pt)
|
2004-05-07 |
2007-11-20 |
Peptimmune Inc |
métodos de tratar doenças com copolìmeros aleatórios
|
US7655221B2
(en)
*
|
2004-05-07 |
2010-02-02 |
Peptimmune, Inc. |
Methods of treating disease with random copolymers
|
WO2005112911A2
(fr)
*
|
2004-05-21 |
2005-12-01 |
The Regents Of The University Of California |
Compositions et procedes de traitement de troubles de deficience de la myeline
|
EP1761276B1
(fr)
|
2004-06-25 |
2013-07-24 |
ID Biomedical Corporation of Quebec |
Compositions et procedes de traitement de troubles neurologiques
|
NZ554018A
(en)
*
|
2004-09-09 |
2009-06-26 |
Teva Pharma |
Process for preparation of trifluoroacetyl glatiramer acetate using purified hydrobromic acid
|
SI1797109T1
(sl)
*
|
2004-09-09 |
2016-07-29 |
Yeda Research And Development Co., Ltd. |
Zmesi polipeptidov, sestavki, ki jih vsebujejo, in postopki za njihovo pripravo ter njihove uporabe
|
CA2583589C
(fr)
*
|
2004-10-29 |
2012-04-24 |
Sandoz Ag |
Procedes de preparation d'un glatiramere
|
WO2006083608A1
(fr)
*
|
2005-02-02 |
2006-08-10 |
Teva Pharmaceutical Industries, Ltd. |
Procede de production de melanges de polypeptides par hydrogenolyse
|
JP2009504885A
(ja)
*
|
2005-08-15 |
2009-02-05 |
チャン,ウェイ,ホン |
コポリマー−1の製造方法
|
WO2007092451A2
(fr)
|
2006-02-06 |
2007-08-16 |
The Brigham And Women's Hospital, Inc. |
Polysaccharides zwitterioniques pour favoriser la maturation du système immunitaire et la santé
|
CN101479607B
(zh)
|
2006-04-28 |
2013-10-02 |
莫门塔制药股份有限公司 |
评估肽混合物的方法
|
KR100831796B1
(ko)
*
|
2006-05-29 |
2008-05-28 |
엘지전자 주식회사 |
타임 쉬프트 기능을 내장한 영상표시기기 및 그 재생 방법
|
JP5412280B2
(ja)
|
2006-06-28 |
2014-02-12 |
イエダ リサーチ アンド デベロップメント カンパニー リミテッド |
加齢性黄斑変性症の治療法
|
US20100183658A1
(en)
*
|
2007-03-30 |
2010-07-22 |
The Brigham And Women's Hospital, Inc. |
Novel Compounds for Enhancing MHC Class II Therapies
|
JP2010530975A
(ja)
*
|
2007-06-21 |
2010-09-16 |
モメンタ ファーマシューティカルズ インコーポレイテッド |
コポリマーアッセイ
|
CA2705046C
(fr)
*
|
2007-07-31 |
2015-03-03 |
Natco Pharma Limited |
Procede de preparation de l'acetate de glatiramer (copolymere-1)
|
US20090035816A1
(en)
*
|
2007-08-02 |
2009-02-05 |
Scinopharm Taiwan Ltd. |
Process for the preparation of a polypeptide
|
US8193147B2
(en)
|
2007-09-24 |
2012-06-05 |
Hadasit Medical Research Services & Development Ltd. |
Use of copolymer 1 for treatment of muscular dystrophy
|
WO2009129018A1
(fr)
†
|
2008-04-16 |
2009-10-22 |
Momenta Pharmaceuticals, Inc. |
Analyse de compositions copolymères d'acides aminés
|
BRPI0918718A2
(pt)
*
|
2008-08-07 |
2015-12-01 |
Scinopharm Taiwan Ltd |
síntese de acetato de glatirâmero
|
AR074881A1
(es)
|
2008-12-24 |
2011-02-16 |
Synthon Bv |
Un proceso para purificar una mezcla de polimeros
|
US8859489B2
(en)
*
|
2009-04-03 |
2014-10-14 |
Momenta Pharmaceuticals, Inc. |
Water-mediated control of depolymerization step of glatiramer acetate synthesis
|
EP2438080B1
(fr)
|
2009-06-04 |
2013-12-04 |
Council of Scientific & Industrial Research An Indian registered body incorporated under the Registration of Societies Act (Act XXI of 1860) |
Procédé de préparation de copolymère-1 (cop-1), composé à base de l-alanine, l-lysine, acide l-glutamique et l-tyrosine pour le traitement de la sclérose en plaques
|
US8691790B2
(en)
*
|
2009-07-27 |
2014-04-08 |
James Layne Boucher |
Therapy of neurological inflammatory diseases with (5'-deoxy-5'-adenosyl) cobamamide, recombinant human growth hormone, interleukins IL-1, IL-6, IL-11, epidermal growth factor, and physiotherapy
|
KR20170123354A
(ko)
|
2009-08-20 |
2017-11-07 |
에다 리서치 앤드 디벨럽먼트 컴퍼니 리미티드 |
글라티라머 아세테이트를 포함하는 약제
|
USRE49251E1
(en)
|
2010-01-04 |
2022-10-18 |
Mapi Pharma Ltd. |
Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
|
CN107184954A
(zh)
|
2010-01-04 |
2017-09-22 |
Mapi医药公司 |
包含格拉默或其药用盐的储药系统
|
US8377885B2
(en)
|
2010-01-04 |
2013-02-19 |
Mapi Pharma Ltd. |
Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
|
US20130035390A1
(en)
|
2010-01-13 |
2013-02-07 |
Ramot At Tel-Aviv University Ltd. |
Treatment of multiple sclerosis
|
JP2013541010A
(ja)
|
2010-10-11 |
2013-11-07 |
テバ ファーマシューティカル インダストリーズ リミティド |
グラチラマーアセテートに対する臨床的な反応の予測可能なバイオマーカーとしてのサイトカインバイオマーカー
|
WO2012054518A1
(fr)
*
|
2010-10-18 |
2012-04-26 |
Lanco Biosciences, Inc. |
Administration de copolymères par systèmes de micro-injection
|
CA2827275A1
(fr)
|
2011-02-14 |
2012-09-20 |
Usv Limited |
Copolymere-1, son procede de preparation et methodes d'analyse de celui-ci
|
WO2012143924A1
(fr)
|
2011-04-21 |
2012-10-26 |
Mapi Pharma Ltd. |
Pentapolymère statistique pour le traitement de maladies auto-immunes
|
WO2012150495A1
(fr)
|
2011-05-05 |
2012-11-08 |
National Institute Of Immunology |
Peptides synthétiques et copolymères aléatoires pour le traitement de troubles auto-immuns
|
WO2013009885A2
(fr)
|
2011-07-11 |
2013-01-17 |
Momenta Pharmaceuticals, Inc. |
Evaluation de diéthylamide de copolymère
|
WO2013009864A1
(fr)
|
2011-07-11 |
2013-01-17 |
Momenta Pharmaceuticals, Inc. |
Évaluation de structure de mélanges polypeptidiques hétérogènes
|
EP2731617A4
(fr)
|
2011-07-12 |
2015-07-01 |
Brigham & Womens Hospital |
Compositions de psa contenant des lipides, procédés d'isolement et procédés pour les utiliser
|
US8575198B1
(en)
|
2011-09-07 |
2013-11-05 |
Momenta Pharmaceuticals, Inc. |
In-process control for the manufacture of glatiramer acetate
|
TW201326399A
(zh)
|
2011-10-10 |
2013-07-01 |
Teva Pharma |
用於預測對格拉替雷(glatiramer)醋酸鹽之臨床反應之單核苷酸多型性之判定
|
EP2642290A1
(fr)
|
2012-03-19 |
2013-09-25 |
Synthon BV |
Analyse de la puissance de l'acétate de glatiramère basée sur des lignées de cellules monocytaires humaines
|
WO2013139728A1
(fr)
|
2012-03-19 |
2013-09-26 |
Synthon Bv |
Test d'activité biologique de l'acétate de glatiramère à base de cellules monocytaires humaines
|
TW201420111A
(zh)
|
2012-10-10 |
2014-06-01 |
Teva Pharma |
對格拉默醋酸鹽(glatiramer acetate)之臨床反應具預測性之生物標記
|
WO2014060942A2
(fr)
*
|
2012-10-20 |
2014-04-24 |
Mahesh Kandula |
Compositions et méthodes pour le traitement de la sclérose en plaques et de maladies neurodégénératives
|
PT2774640E
(pt)
|
2013-03-08 |
2015-02-09 |
Teva Pharma |
Dispositivo injector reutilizável para seringa
|
PL2774639T3
(pl)
|
2013-03-08 |
2015-07-31 |
Teva Pharma |
Wielorazowe urządzenie strzykawkowe dla strzykawki
|
JP6553018B2
(ja)
|
2013-03-14 |
2019-07-31 |
マイラン・インコーポレイテッドMylan Inc. |
酢酸グラチラマー応答バイオマーカーmRNA効力アッセイ
|
WO2014173463A1
(fr)
|
2013-04-26 |
2014-10-30 |
Synthon Bv |
Test d'activité biologique basé sur les lignées cellulaires monocytaires humaines au moyen d'acétate de glatiramère
|
CN103265624B
(zh)
*
|
2013-05-27 |
2015-04-22 |
成都圣诺生物制药有限公司 |
格拉替雷的制备方法
|
UY35790A
(es)
|
2013-10-21 |
2015-05-29 |
Teva Pharma |
Marcadores genéticos que predicen la respuesta al acetato de glatiramer
|
US9995734B2
(en)
|
2013-10-24 |
2018-06-12 |
Mylan Inc. |
Human T cell line assay for evaluating the immunologic identity of glatiramer acetate preparations
|
EP3090064B1
(fr)
|
2013-12-31 |
2019-11-13 |
Yeda Research and Development Co. Ltd. |
Diagnostic du lupus érythémateux systémique à l'aide d'oligonucléotides antigènes
|
US10144778B2
(en)
|
2014-03-12 |
2018-12-04 |
Yeda Research And Development Co. Ltd |
Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
|
WO2016029920A1
(fr)
|
2014-08-29 |
2016-03-03 |
Aarhus Universitet |
Copolymères à charge positive destinés à être utilisés en tant qu'agents antimicrobiens
|
US9155775B1
(en)
|
2015-01-28 |
2015-10-13 |
Teva Pharmaceutical Industries, Ltd. |
Process for manufacturing glatiramer acetate product
|
EP3265814B1
(fr)
|
2015-03-01 |
2020-11-18 |
Immunarray Ltd. |
Diagnostic du lupus érythémateux systémique à l'aide d'antigènes protéiques, peptidiques et oligonucléotidiques
|
JP6918365B2
(ja)
|
2015-08-19 |
2021-08-11 |
プレジデント アンド フェローズ オブ ハーバード カレッジ |
脂質化psa組成物および方法
|
ES2744179T3
(es)
|
2015-09-24 |
2020-02-24 |
Chemi Spa |
Análisis de la distribución de peso molecular de mezclas de polipéptidos complejas
|
ES2707500T3
(es)
|
2015-11-23 |
2019-04-03 |
Chemi Spa |
Análisis mediante RP-HPLC de mezclas de polipéptidos complejos
|
US20210220428A1
(en)
|
2016-06-30 |
2021-07-22 |
Stem Cell Medicine Ltd. |
Treatment of inflammatory bowel disease with long acting glatiramer and adipose-derived stem cells
|
CA3030974A1
(fr)
|
2016-07-15 |
2018-01-18 |
President And Fellows Of Harvard College |
Compositions de glycolipide et procedes d'utilisation
|
CN110382052A
(zh)
|
2017-03-26 |
2019-10-25 |
Mapi医药公司 |
用于治疗进展型形式的多发性硬化症的格拉替雷储库系统
|
WO2018211498A1
(fr)
|
2017-05-15 |
2018-11-22 |
Stem Cell Medicine Ltd. |
Traitement de la sclérose en plaques avec des cellules souches dérivées du tissu adipeux
|
EP3624815A4
(fr)
|
2017-05-15 |
2021-01-20 |
Stem Cell Medicine Ltd. |
Traitement de la sclérose en plaques avec un glatiramère à action prolongée et des cellules souches dérivées du tissu adipeux
|
WO2019175869A1
(fr)
|
2018-03-12 |
2019-09-19 |
Yeda Research And Development Co. Ltd |
Traitement d'une maladie cardiaque
|